Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nyse
  5. Johnson & Johnson
  6. News
  7. Summary
    JNJ   US4781601046

JOHNSON & JOHNSON

(JNJ)
  Report
Delayed Nyse  -  04:00 2022-06-27 pm EDT
182.12 USD   -0.09%
08:12aMeiraGTx Sees Positive Data From Phase 1/2 Trial of Botaretigene Sparoparvovec for X-Linked Retinitis Pigmentosa Patients
MT
06/27Janssen Receives Positive CHMP Opinion for IMBRUVICA (ibrutinib) in a Fixed-Duration Combination Regimen for Adult Patients with Previously Untreated Chronic Lymphocytic Leukaemia (CLL)
AQ
06/24Johnson & Johnson's Janssen Receives EU Medicines Agency Panel's Backing for Leukemia Drug
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Transcript : Johnson & Johnson Presents at UBS Global Healthcare Conference, May-24-2022 10:00 AM

05/24/2022 | 10:00am EDT
share with twitter
share with LinkedIn
share with facebook
Good morning, everyone, and welcome back to day 2 of the UBS Global Healthcare Conference. I'm delighted to be joined on stage by Dr. Mathai Mammen, who is Head of Pharmaceuticals R&D at Johnson...


© S&P Capital IQ 2022
All news about JOHNSON & JOHNSON
08:12aMeiraGTx Sees Positive Data From Phase 1/2 Trial of Botaretigene Sparoparvovec for X-Li..
MT
06/27Janssen Receives Positive CHMP Opinion for IMBRUVICA (ibrutinib) in a Fixed-Duration Co..
AQ
06/24Johnson & Johnson's Janssen Receives EU Medicines Agency Panel's Backing for Leukemia D..
MT
06/24Johnson & Johnson's Unit Janssen Says EMA's Committee Backs Approval of Imbruvica to Tr..
MT
06/24JOHNSON & JOHNSON'S JANSSEN : CHMP Backs Expanded Imbruvica Use in Chronic Lymphocytic Leu..
DJ
06/23JOHNSON & JOHNSON : Renews Commitment to Fight Neglected Tropical Diseases, Investing in B..
PU
06/22WALL STREET STOCK EXCHANGE : Powell's tall order to reassure investors
06/22Daiwa Securities Starts Johnson & Johnson at Outperform With $180 Price Target
MT
06/22ANALYST RECOMMENDATIONS : Johnson & Johnson, NatWest, Home Depot, Kraft Heinz, Vodafone...
06/21TRANSCRIPT : Johnson & Johnson - Special Call
CI
More news
Analyst Recommendations on JOHNSON & JOHNSON
More recommendations
Financials (USD)
Sales 2022 96 499 M - -
Net income 2022 22 521 M - -
Net cash 2022 8 885 M - -
P/E ratio 2022 21,2x
Yield 2022 2,45%
Capitalization 479 B 479 B -
EV / Sales 2022 4,87x
EV / Sales 2023 4,58x
Nbr of Employees 141 700
Free-Float 84,2%
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Last Close Price 182,12 $
Average target price 188,12 $
Spread / Average Target 3,29%
EPS Revisions
Managers and Directors
Joaquin Duato Chief Executive Officer & Director
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Matthew Stuckley Senior Financial Analyst-Janssen Commercial Pharm
Alex Gorsky Executive Chairman
Peter Shen Global Head-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON6.56%479 678
ELI LILLY AND COMPANY17.88%293 110
PFIZER, INC.-12.63%289 466
ROCHE HOLDING AG-15.91%272 090
ABBVIE INC.12.51%269 202
NOVO NORDISK A/S6.98%253 053